Loading
Every dated change on the records linked to Breast cancer (all types), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Early-stage HER2+ breast cancer (neoadjuvant and post-neoadjuvant)
This is the decision with a deadline. Chemotherapy can stop the ovaries working, temporarily or permanently, and treatment can bring the menopause forward by decades; once treatment has started, some of the options have gone. NICE NG101 (1.1.5) hands fertility preservation to the NICE fertility guideline, now NG257 (2026), and NG257 (1.53.1) says to discuss it with people preparing for treatment likely to impair their fertility, and that where treatment is urgent the discussion should happen at the earliest possible opportunity. The route it names is (1.53.6) oocyte or embryo cryopreservation for people of reproductive age with female reproductive organs, (1.53.5) sperm cryopreservation for those with male reproductive organs, which matters because men get breast cancer too, and (1.53.7) ovarian tissue cryopreservation where the others are not feasible. Two sentences in NG257 are worth carrying into the room. The first is (1.53.3): for NHS-funded fertility preservation, do not apply the eligibility criteria used for conventional fertility treatment, including the lower age limit. The rules about age, existing children and BMI that govern NHS IVF are not supposed to be applied to preserving fertility before cancer treatment. The second is (1.53.4): those criteria will apply later, when you come to use the stored material, so the funding question has two halves and it is worth asking both. Storage is reviewed at least every 5 years and NHS funding continues for people who remain at significant risk (1.53.8). On timing, Cancer Research UK says collecting and freezing eggs takes about 2 to 3 weeks, that IVF is the most effective method, that letrozole or tamoxifen can be used with lower-dose stimulation, and that IVF is available for some people on the NHS but not everywhere, so the answer varies by where you live. Where there is no time for any of that, the other route is switching the ovaries off during chemotherapy with a GnRH agonist injection. In an individual patient-level meta-analysis of 873 patients from five randomised trials, premature ovarian insufficiency occurred in 14.1 percent of those given a GnRH agonist against 30.9 percent of controls (adjusted odds ratio 0.38), and at least one pregnancy after treatment in 10.3 against 5.5 percent, with no significant difference in disease-free or overall survival. The trial that opened this question, POEMS, randomised 257 premenopausal women with operable hormone receptor-negative breast cancer and found ovarian failure at 2 years in 8 percent on goserelin against 22 percent, with pregnancy in 21 against 11 percent. Whether this is offered as well as, or instead of, egg freezing is a conversation for the fertility clinic rather than a substitute for it. If the menopause arrives anyway, it arrives fast and without the years of warning a natural menopause gives. NICE NG101 (1.14.20) says to offer women information and counselling about the possibility of early menopause and its symptoms, and (1.14.21) to stop systemic HRT at diagnosis. On treating the symptoms it is restrictive and says so: (1.14.22) do not routinely offer HRT to women with a history of breast cancer; (1.14.23) offer it in exceptional circumstances for severe symptoms after discussing the risks; (1.14.24) consider an SSRI for hot flushes, but not for women taking tamoxifen; and (1.14.25) do not offer soy, red clover, black cohosh, vitamin E or magnetic devices. Bone follows: (1.14.26) offer a baseline DEXA scan to women not on adjuvant bisphosphonates who are starting an aromatase inhibitor, have a treatment-induced menopause, or are starting ovarian suppression; (1.14.27) not to those on tamoxifen alone; and (1.14.28) bisphosphonates for those the UK expert group algorithms identify. Whether it is safe to pause endocrine therapy to try for a baby is a question for hormone receptor-positive disease and is answered on that page.
Published 3 July 2025 and recommended from 1 January 2026. For breast the classification is unchanged; the yp classification is clarified, basing ypT on the largest continuous focus of residual invasive cancer and recommending that the residual cancer burden be reported beside it.
Published April 2026. Reserves 'variant' for molecular alterations and separates subtype from pattern, updates the HER2 reporting categories so that no membrane staining is distinguished from any, recognises lobular carcinoma with extracellular mucin, moves high-grade and receptor-negative mucinous carcinomas into no special type, drops the unified neuroendocrine model for the breast, and lowers malignant phyllodes tumour to four of five adverse criteria.
HER2-low and HER2-ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)
HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy (TROPION-Breast01)
HR-positive, HER2-negative unresectable or metastatic breast cancer after endocrine therapy and at least one line of chemotherapy; marketing authorisation issued 4 April 2025. No triple-negative indication in the EU on 24 September 2026
HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy
HER2-low/ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)
Five-year invasive disease-free survival 91.
Regional nodal irradiation after a complete nodal response to chemotherapy did not lengthen the invasive breast cancer recurrence-free interval (hazard ratio 0.
Implant loss 8.
Ten-year overall survival 81.
Axillary surgery omitted in 4,858 patients, regional nodal irradiation dropped after a complete nodal response, and no survival gain from chest-wall radiotherapy in intermediate-risk disease.
HER2-low metastatic or unresectable breast cancer after chemotherapy: NICE TA992 (29 July 2024) does not recommend trastuzumab deruxtecan, the cost per quality-adjusted life year being above the range NICE accepts; a rapid review (GID-TA12551) is in development
Oestrogen receptor, progesterone receptor and HER2 assessed simultaneously on the diagnostic biopsy by quality-assured immunohistochemistry, reported quantitatively, with reflex in situ hybridisation for a HER2 score of 2+, and the results available at both the preoperative and the postoperative multidisciplinary meeting. The pathology report also carries the histological type, the Nottingham grade with its three component scores, the invasive and whole tumour size, the node stage and the margins.
At two years the rate of ipsilateral invasive cancer with active monitoring was non-inferior to guideline-concordant surgery.
Ongoing; the first block results and de-escalation rates were reported from 2024.
Palbociclib added to maintenance anti-HER2 and endocrine therapy lengthened progression-free survival.
Five-year recurrence-free survival 89.
RCPath G148 version 3 (November 2024) adds the ER low positive category, a separate section on male breast disease, updated handling of specimens after neoadjuvant treatment, and an appendix on assessing tumour cellularity for molecular testing. Full review is due November 2026.
Unresectable or metastatic HER2-low breast cancer after chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy (DESTINY-Breast04), hormone-receptor-negative disease included
Ten-year axillary recurrence 1.
5-year local recurrence 2.
Five-year distant disease-free survival 98.
Very high three-year invasive disease-free survival with one year of trastuzumab emtansine in stage I disease, but clinically relevant toxicity was not lower than with paclitaxel plus trastuzumab.
One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival.
Recruitment closed March 2020; the mortality endpoint is not due until the trial ends in December 2031 (ISRCTN33292440).
At ten years, 28.
5-year ipsilateral breast tumour relapse 1.
Breast cancer in 85 of 1,920 on anastrozole against 165 of 1,944 on placebo after a median 131 months, hazard ratio 0.
Neratinib plus capecitabine improved progression-free survival over lapatinib plus capecitabine and reduced interventions for central nervous system disease; approved in February 2020.
Circulating tumour DNA matched tissue genotyping with about 93 percent sensitivity; neratinib (HER2 mutations) and capivasertib plus fulvestrant (AKT1 mutations, receptor-positive) met their response thresholds; extended-dose fulvestrant for ESR1 mutations did not.
Continuous cohort reporting: positive signals for pembrolizumab in high tumour mutational burden cancers and trastuzumab plus pertuzumab in ERBB2-amplified colorectal cancer; palbociclib in CDKN2A-altered lung cancer and several other matches were negative.
Five-year local recurrence 2.
26 Gy in five fractions non-inferior to 40 Gy in fifteen at five years; adopted across the United Kingdom and accelerated by the pandemic.
HER2+ metastatic breast cancer, ≥2 prior anti-HER2 regimens
Within three months of immediate implant-based reconstruction: implant loss 9 percent, infection needing treatment 25 percent, return to theatre 18 percent and readmission 18 percent, all above the National Quality Standards.
10-year ipsilateral breast tumour recurrence 4.
Eight-year ipsilateral breast tumour recurrence 3.
Tamoxifen 5 mg daily for three years roughly halved breast cancer events compared with placebo with few serious adverse effects.
Keeps invasive carcinoma of no special type as the default group and folds the former medullary, oncocytic, lipid-rich, glycogen-rich, sebaceous and pleomorphic carcinomas into it as patterns. This is the edition UK reports are written against in 2026.
Start with the thing almost nobody is told before they consent. Breast and armpit surgery cuts small sensory nerves, so an area of the chest, the breast, the armpit and the upper inner arm is numb afterwards. Cancer Research UK puts it as numbness, tingling or a shooting pain in the armpit, upper arm, shoulder or chest wall from nerve damage during surgery, and says the nerves usually repair themselves but it can take many weeks or months. The longer-term picture comes from a Danish national survey: of 3,253 women aged 18 to 70 who answered a median of 26 months after surgery, 1,543 (47 percent) reported pain in the treated area, 201 of them severe and 595 moderate; the odds of persistent sensory disturbance were about five times higher after axillary lymph node dissection than after sentinel lymph node dissection (odds ratio 4.97, 3.92 to 6.30) and five times higher in women aged 18 to 39; radiotherapy raised the odds of pain and chemotherapy did not. Only about 1 in 5 of those in pain had spoken to a doctor about it in the previous three months, which is the second half of the problem: it is treatable, and people do not report it because they were never told to expect it. A reconstructed breast has little or no sensation however good it looks, and a spared nipple usually has none. Cancer Research UK says the new breast will feel and look different to the one removed. That is worth asking about separately from appearance, before the operation, because it is not something a photograph shows. On the body you are left with: Cancer Research UK says swelling and bruising go down and scars fade, but it may take up to a year for things to settle, and that the first few months can bring intense feelings. NICE NG101 (1.1.2) says to offer all people with breast cancer prompt access to specialist psychological support and, where appropriate, psychiatric services, which makes asking for it a request for something already promised. Breast Cancer Now's Someone Like Me pairs people with a volunteer who has been through something similar, and Maggie's centres are free and need no appointment. On sex, plainly. Cancer Research UK says breast surgery does not affect your ability to have sex, but that emotions may change sexual feelings for a while and that you might worry about letting a partner see or touch your body. The physical obstacles are usually treatable and usually unmentioned: numbness where the breast used to respond, a chest wall that hurts to lie on, shoulder stiffness that makes positions awkward, fatigue, and, where treatment has forced the menopause, vaginal dryness and pain, which is a symptom with treatments rather than something to endure. NICE NG101 (1.14.20) puts information and counselling about menopausal symptoms into the guideline. Nothing here assumes the reader is a woman, has a partner, is heterosexual, or has stopped wanting sex. Men with breast cancer have their own page and the same conversation is owed to them; the NHS does not routinely offer implant reconstruction to men because the implants available do not recreate the shape of a man's chest, which makes the scar and the sensation the whole of the outcome.
This is the decision the whole of early breast cancer turns on, and it is usually presented as a choice with the same outcome. That is true of survival and of almost nothing else, so it is worth having the actual numbers. Two randomised trials followed people for twenty years. In the Milan trial, 701 women with cancers no larger than 2 cm were assigned between 1973 and 1980 to radical (Halsted) mastectomy or to quadrantectomy followed by radiotherapy; after a median 20 years, death from any cause had occurred in 41.2 percent of the mastectomy group and 41.7 percent of the conserving group (P equals 1.0), and death from breast cancer in 24.3 and 26.1 percent (P equals 0.8). In NSABP B-06, 1,851 women were assigned to total mastectomy, lumpectomy alone, or lumpectomy with radiotherapy, and after 20 years there was no significant difference between the three in disease-free, distant-disease-free or overall survival, with a hazard ratio for death of 0.97 (0.83 to 1.14) for lumpectomy with radiotherapy against total mastectomy. Those are the cohorts they are: women treated decades ago, with the surgery and drugs of the time, and they say nothing about what will happen to one person. What they do say is that keeping the breast did not cost survival, which is why it is offered first. What differs is everything else, and this is the part usually summarised away. Radiotherapy: conserving surgery commits you to it. NICE NG101 (1.13.3) says to offer whole-breast radiotherapy after breast-conserving surgery with clear margins, and (1.13.13) 26 Gy in 5 fractions over 1 week where the lymph nodes are not being treated, or (1.13.14) 40 Gy in 15 fractions over 3 weeks where there is a reason including implant-based reconstruction, and (1.13.16) 40 Gy in 15 fractions whenever the nodes are irradiated. Mastectomy does not reliably avoid it: NG101 (1.13.10) offers radiotherapy after mastectomy for node-positive disease or involved margins, and (1.13.12) withholds it from most node-negative disease. What radiotherapy is worth after conserving surgery has been measured: in the EBCTCG meta-analysis of 10,801 women in 17 randomised trials, it cut the 10-year risk of any first recurrence from 35.0 to 19.3 percent and the 15-year risk of breast cancer death from 25.2 to 21.4 percent, with about one breast cancer death avoided by year 15 for every four recurrences avoided by year 10. For a narrow low-risk group NICE offers the choice of leaving it out: NG101 (1.13.7, 1.13.8) says to consider not using radiotherapy for women aged 65 and over with T1N0, ER-positive, HER2-negative, grade 1 to 2 cancer who will take endocrine therapy for at least 5 years, and to tell them that without radiotherapy local recurrence occurs in about 50 women per 1,000 at 5 years against about 10 per 1,000 with it, that overall survival at 10 years is the same, and that there is no increase in serious late effects from having it. A second operation: conserving surgery can need one. NG101 (1.4.3) offers further surgery where cancer is at the inked margin and (1.4.5) considers it within 1 mm, and the 2024 committee lowered that threshold from 2 mm precisely because repeated surgeries damage breast appearance and self-esteem, are traumatic, and vary in frequency across the country. How the breast looks and feels: after conserving surgery the treated breast can be smaller, firmer or dented, and NICE's own radiotherapy evidence records more clinician-assessed adverse events at 5 years and more reports of a harder or firmer breast with the one-week schedule, though it judged the differences not clinically important. After mastectomy the chest is numb over the scar whatever is done next. And what recurrence would mean: in the Milan trial, 30 of 352 women treated by quadrantectomy and radiotherapy had a recurrence in the same breast over 20 years, a crude cumulative incidence of 8.8 percent, against 8 local recurrences among 349 after radical mastectomy, 2.3 percent, with no difference in distant metastases; NSABP B-06 put in-breast recurrence at 14.3 percent over 20 years with radiotherapy and 39.2 percent without. A recurrence in a conserved breast is a further operation and a frightening year; it did not, in these trials, change survival. Finally, some cancers do not offer the choice. Macmillan lists the reasons a mastectomy is recommended: a lump large compared with the rest of the breast, cancer in different parts of the breast, widespread DCIS, cancer on the skin or in the underlying muscle, previous radiotherapy to the chest, or a gene mutation found on testing.
It is the first question people ask and the one answered with the least detail, so here is what is known. Not every breast cancer treatment causes hair loss: it depends on the drugs, which depend on the receptor result, and the subtype pages list the regimens. Where it happens, Macmillan says it usually starts after the first or second treatment, that eyebrows and eyelashes can go as well, and that hair usually starts to grow back after treatment, sometimes with a different texture or colour. Scalp cooling is the only thing that changes the outcome. In the SCALP randomised trial, 50.5 percent of women cooled during taxane, anthracycline or both kept more than half their hair after the fourth cycle, against none of the controls. That is the honest headline: about half kept enough hair to go without a wig, and about half did not, and the trial counted keeping more than half rather than keeping all of it. The figure is better with taxane-only regimens and worse with anthracyclines. A caveat that belongs beside every one of those numbers: the trials that produced them had few Black participants, and a later phase II study of the Paxman device in Black patients having chemotherapy for stage I to III breast cancer closed early after 15 of a planned 30 participants for lack of efficacy, with hair loss and distress scores rising during cooling and only one participant avoiding significant loss; the authors named hair thickness, hair volume and cap design as the likely reasons. Anyone quoting one in two should say whose hair it was measured on. Practically, cooling means wearing a tight cold cap from before the infusion until some time after it, so treatment days get longer, and it is uncomfortable at the start. Availability varies by unit, so whether it is offered at all is a question for the first chemotherapy appointment rather than the third. If you would want a wig, Macmillan says to get it before treatment starts, because matching your own colour and style is easier while you still have it and you can get used to wearing it; buying and practising with eyebrow and eyelash products beforehand works the same way. Some people shave their heads first for the sense of control. The Little Princess Trust provides free real-hair wigs to people up to the age of 24. None of this is vanity. Hair is how most people are recognised, including by themselves, and losing it is often the moment a diagnosis becomes visible to everyone else.
Three options, not two, and the third is a real one. NICE NG101 (1.5.1) says to offer breast reconstruction to people after they have had a mastectomy for breast cancer, and immediately afterwards (1.5.2) to be aware that some people may prefer not to have it. It also says (1.5.3) to offer both the immediate and the delayed option whether or not they are available locally, which is the sentence to quote when a local service offers only one, and (1.5.4) to offer immediate reconstruction to women advised to have a mastectomy including those who may need radiotherapy, unless comorbidities rule out reconstructive surgery. On timing, NG101's table 1 is unusually frank. Immediate reconstruction means waking with a breast shape, usually fewer operations and anaesthetics, and less scarring because the existing breast skin is used, but limited time to decide, a longer operation and recovery, and a risk that complications delay chemotherapy or radiotherapy; Cancer Research UK notes that there is good evidence chemotherapy works best started within 6 weeks of cancer surgery. Delayed reconstruction means a period with no breast, which a prosthesis can fill, but more time to choose, time to lose weight or stop smoking first, and a reconstruction that cannot be derailed by the cancer treatment. Both, NICE says, usually need more than one operation to complete, and there are no clear differences in satisfaction with completed reconstructions either way. On what each option asks of the body: an implant is the simplest operation and the shortest recovery, but NICE notes that implant-based reconstructions may be more affected by radiotherapy than flap reconstructions, and where radiotherapy is planned the route is often a tissue expander first and an exchange later, which is two operations. A flap moves skin, fat and sometimes muscle from the tummy or the back, gives a breast that ages and changes weight with you, and costs a second wound, a longer operation, a longer recovery and, where the tummy is used, a risk of hernia that smoking increases. Both carry flap or implant failure, which NICE says may lead to delayed reconstruction and a flat appearance for a period of time. Surgery to the other breast to match, called contralateral symmetrisation, is common and can be done at the same time or later. Whatever is built, Cancer Research UK says plainly that the new breast will feel and look different to the one removed: it is a shape rather than a restored breast, and it has little sensation. Choosing none is not a failure to decide. A prosthesis, specialist mastectomy wear, or nothing at all are all ordinary, and a surgeon can often make a flat chest wall even rather than leaving loose skin. For men the NHS does not routinely do implant reconstruction, because the implants available do not recreate the shape of a man's chest. After breast-conserving surgery there is a smaller version of the same conversation: where a large amount of tissue is removed the breast can be left with a dent, and a partial reconstruction using nearby tissue, or reshaping the breast (therapeutic mammoplasty, often with a reduction on the other side), can be done at the same operation. Radiotherapy still follows.
The armpit operation is decided almost in passing and is the single biggest determinant of how the arm feels for the rest of your life, so it is worth understanding. NICE NG101 (1.2.1) has the axilla scanned before treatment and any abnormal node sampled with a needle. If that is clear, (1.4.9) says to stage the axilla with a sentinel lymph node biopsy rather than a clearance, using (1.4.10) the dual technique of isotope and blue dye; Macmillan says this removes the smallest number of nodes possible, usually 1 to 3. If the needle biopsy already proved cancer in a node, (1.4.11) says to offer axillary node clearance. If a sentinel node turns out to contain cancer, (1.4.12) says to offer further axillary treatment, clearance or radiotherapy, for 1 or more macrometastasis; (1.4.13) says to discuss the benefits and risks of having no further treatment with women who have 1 or 2 macrometastases, have had conserving surgery, and are having whole-breast radiotherapy with systemic therapy; (1.4.14) says not to treat micrometastases further; and (1.4.15) says isolated tumour cells count as node-negative. The reason all of that exists is lymphoedema, and the figures are the part nobody hears. In a meta-analysis of 72 studies, the pooled incidence of arm lymphoedema after breast cancer was 16.6 percent, and 21.4 percent when restricted to 30 prospective cohorts, rising over the first two years; it was about four times higher after axillary lymph node dissection (19.9 percent) than after sentinel node biopsy (5.6 percent), and the risk factors with the strongest evidence were extensive surgery and being overweight or obese. That is where more than one in five comes from. Radiotherapy to the axilla instead of surgery roughly halves it: in AMAROS, 1,425 sentinel node-positive patients were randomised, and at 5 years lymphoedema affected 24.5 percent after clearance against 11.9 percent after axillary radiotherapy, while at 10 years axillary recurrence was 0.93 against 1.82 percent with no difference in survival. Two trials go further and leave the axilla alone: in ACOSOG Z0011, 891 women with 1 or 2 positive sentinel nodes having lumpectomy and whole-breast radiotherapy had 10-year overall survival of 86.3 percent without clearance against 83.6 percent with it, and in SENOMAC, 2,540 patients with 1 or 2 sentinel-node macrometastases, about 90 percent of them having nodal radiotherapy, had 5-year recurrence-free survival of 89.7 against 88.7 percent. What reduces the risk, in NICE's own 2025 words: information before treatment starts in a format to take away, covering risk reduction, early signs, skin changes, how to self-monitor and how to take baseline measurements of the limb (1.14.1); keeping to a healthy weight and keeping the arm moving, because (1.14.3) physical activity does not cause or worsen lymphoedema and may improve quality of life; and skin care, because infection is what tips a vulnerable arm over. NICE also clears away some folklore: (1.14.1) says there is no consistent evidence of increased risk from air travel, travel to hot countries, manicures, hot tub use or sports injuries, nor from blood tests, injections, intravenous medicines or blood pressure measurement on the treated side, and (1.14.2) makes procedures on that arm a shared decision rather than a prohibition. It says (1.14.4) not to offer compression garments as prevention to people who are only at risk. Recognising it early is the whole game. Breast Cancer Now describes swelling that comes and goes and is worse at the end of the day, rings and watches suddenly tight, tightness in the arm or breast without visible swelling, a dull ache, heaviness, tingling or numbness, dry skin, and later hardness or pins and needles. NICE (1.14.6) says to refer anyone who develops it to a specialist lymphoedema service as soon as possible. Treatment exists and works: (1.14.8) assess for other causes such as nodal disease or cellulitis first, (1.14.9) compression therapy as the first stage with a shared decision about the form, (1.14.10) kinesiology tape if compression is not tolerated, and (1.14.11) reassurance that exercise is safe. The NHS calls the whole package decongestive lymphatic therapy: compression, skin care, exercise and specialised massage, then a maintenance phase you run yourself. It is controlled rather than cured, which is why it is worth catching in the first weeks. Alongside lymphoedema sits the shoulder. NG101 (1.14.14) says to identify people as high risk before surgery if they have a pre-existing shoulder problem, a BMI over 30, planned axillary node clearance, or planned radiotherapy to the axilla or supraclavicular nodes, (1.14.16) to offer them supervised support with upper limb exercises, and (1.14.19) to refer anyone with a persistent reduction in arm and shoulder mobility to physiotherapy.
Follow-up after breast cancer is lighter than most people expect, and the reason is that scans of people without symptoms have never been shown to help. NICE NG101 (1.15.1) says to offer annual mammography for 5 years to everyone who has had or is being treated for breast cancer including DCIS, and for women to continue annual mammography past 5 years until they enter the NHS Breast Screening Programme in England or the Breast Test Wales Screening Programme; (1.15.2) not to do mammography of the ipsilateral soft tissues after a mastectomy; and (1.15.3) not to use routine ultrasound or MRI for post-treatment surveillance. That first rule is under revision: NICE reviewed the guideline on 11 September 2026 and says it will be updating the recommendation on annual mammography, following a surveillance decision taken in June 2026, with no new wording published yet. What replaces the scans is a document and a phone number. NG101 (1.15.4) says to ensure everyone who has had treatment has an agreed written care plan, recorded in the notes by a named professional and copied to them and their GP, that names the designated healthcare professionals, the dates for reviewing any adjuvant therapy, the details of surveillance mammography, the signs and symptoms to look out for and seek advice on, the contact details for immediate referral to specialist care, and the contact details for support services such as lymphoedema. If you do not have that piece of paper, asking for it is asking for something the guideline already promised. Which symptoms count. Breast Cancer Now gives a three-part rule that is easier to hold than a list: talk to your GP or breast care nurse about any symptom that is new, has no obvious cause, and does not go away, and it says the same rule applies to people already living with secondary breast cancer, where a new symptom may mean the cancer is progressing. Its organ-by-organ list is the one to keep: in the bone, pain that does not improve with painkillers and may be worse lying down or at night, a fracture, or unexplained back pain with difficulty walking, numbness or loss of bladder or bowel control; in the lungs, breathlessness on activity or at rest, a cough that does not go away, or chest pain or tightness that persists; in the liver, pain under the right ribs or in the right shoulder, sickness, loss of appetite and weight, hiccups, a swollen abdomen or yellowing of the skin; in the brain, headache, morning sickness or vomiting, weakness or numbness down one side, unsteadiness, seizures, speech or vision problems, or changes in behaviour or memory; in the skin or the chest wall, a rash, a change in skin colour, or a firm painless lump; and in the lymph nodes, a lump or swelling under the arm, breastbone or collarbone. Three general ones sit above the list: constant tiredness, constant nausea, and unexplained weight loss and loss of appetite. The point of writing them down is not to make the reader watch for cancer in every ache. It is that the three-part test, new plus unexplained plus persistent, is what distinguishes the ache that needs a call from the one that does not, and having it in advance is what stops people waiting months out of a wish not to make a fuss. Alongside all of this, NG101 (1.4.16, 1.4.17) asks every breast unit to audit its local, regional, distant and axillary recurrence rates, including radial margins and demographic information such as socioeconomic status, age and ethnicity, which is a fair thing to ask your own unit about.
Ten-year disease-free survival 76.
At two years, autologous reconstruction gave higher satisfaction with breasts (7.
Used for all breast tumours diagnosed after 1 January 2018. The Royal College of Pathologists reprints it and advises against substituting the American AJCC 8th edition, whose prognostic stage folds grade and receptors into the stage number.
Ten-year overall survival 86.
5-year local relapse 0.
Ten-year overall survival 86.3 percent without completion clearance against 83.6 percent with it.
Multiple graduations (veliparib-carboplatin, neratinib, pembrolizumab, MK-2206, T-DM1 plus pertuzumab, durvalumab plus olaparib, cemiplimab plus fianlimab); pembrolizumab's graduation preceded its approval in early triple-negative breast cancer.
Adding the clipped node to sentinel node dissection cut the false-negative rate from 10.
Ongoing pragmatic trial of risk-based versus annual screening.
Twenty-year ipsilateral breast recurrence 12.
10-year overall survival 82.
Breast cancer in 251 of the tamoxifen arm against 350 of the placebo arm at a median 16 years, hazard ratio 0.
10-year disease-free survival 82.
10-year local recurrence 9.
False-negative rate of sentinel node surgery after chemotherapy 12.
Ten-year local-regional relapse 6.
Cycle 1 mean duration of severe neutropenia 0.
Everolimus plus exemestane more than doubled progression-free survival compared with exemestane alone; approved in July 2012.
At a median 22.
Pathological complete response and early MRI volume change predicted recurrence-free survival, most strongly in triple-negative, HER2-positive and MammaPrint high-risk tumours.
Metastatic breast cancer; later pancreatic (2013) and non-small-cell lung cancer (2015)
10-year local-regional relapse 4.
Twenty-year same-breast recurrence 8.
No significant difference in disease-free, relapse-free, distant-disease-free or overall survival between radical mastectomy, total mastectomy with irradiation and total mastectomy alone, at twenty-five years.
Twenty-year recurrence in the treated breast 14.
NSABP B-06 and Milan I both report at twenty years and NSABP B-04 at twenty-five, none of them finding a survival advantage for the larger operation.